396730-26-0 Usage
Structure
A bicyclic organic compound with an acetyl group attached to the nitrogen atom.
Derivative of
1,6-diazabicyclo[3.2.1]octane
Potential applications
Pharmaceutical industry
Chemical properties
Influenced by the acetyl group attached to the nitrogen atom
Synthesis
Used in the synthesis of other organic compounds
Handling and storage
Careful handling and storage required due to potential reactivity and toxicity
Chemical classification
9CI (Chemical Abstracts Service Registry Number)
Biological properties
Unknown, but may be influenced by the acetyl group
Reactivity
Potentially reactive due to the presence of the acetyl group
Toxicity
Potentially toxic, requiring careful handling and storage
Appearance
Unknown, but likely a solid or liquid depending on the conditions
Solubility
Unknown, but may be soluble in organic solvents
Stability
Unknown, but may be sensitive to heat, light, or moisture
Purity
Unknown, but may require purification techniques to obtain a pure sample for research or pharmaceutical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 396730-26-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,6,7,3 and 0 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 396730-26:
(8*3)+(7*9)+(6*6)+(5*7)+(4*3)+(3*0)+(2*2)+(1*6)=180
180 % 10 = 0
So 396730-26-0 is a valid CAS Registry Number.
396730-26-0Relevant articles and documents
Heterocyclic compounds as inhibitors of beta-lactamases
-
, (2008/06/13)
This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. 1
